WO2008109005A3 - Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers - Google Patents
Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers Download PDFInfo
- Publication number
- WO2008109005A3 WO2008109005A3 PCT/US2008/002747 US2008002747W WO2008109005A3 WO 2008109005 A3 WO2008109005 A3 WO 2008109005A3 US 2008002747 W US2008002747 W US 2008002747W WO 2008109005 A3 WO2008109005 A3 WO 2008109005A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunotoxins
- protein
- synthesis
- cell cancers
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the discovery that contacting CD22+-cancer cells with both an anti-CD22 immunotoxin whose toxin portion is a protein synthesis inhibitor and a chemotherapeutic agent that inhibits protein synthesis results in greater cytotoxicity to the cells than would be expected. This synergistic effect can be exploited to inhibit the growth of CD22+ B cell cancers.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89281907P | 2007-03-02 | 2007-03-02 | |
US60/892,819 | 2007-03-02 | ||
US89359607P | 2007-03-07 | 2007-03-07 | |
US60/893,596 | 2007-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008109005A2 WO2008109005A2 (en) | 2008-09-12 |
WO2008109005A3 true WO2008109005A3 (en) | 2009-01-08 |
Family
ID=39595606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/002747 WO2008109005A2 (en) | 2007-03-02 | 2008-02-28 | Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008109005A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003027135A2 (en) * | 2001-09-26 | 2003-04-03 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
WO2003045429A2 (en) * | 2001-11-28 | 2003-06-05 | Novartis Ag | Anti-t cell immunotoxin fusion protein and its therapeutic use |
WO2005052006A2 (en) * | 2003-11-25 | 2005-06-09 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
WO2007016150A2 (en) * | 2005-07-29 | 2007-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Mutated pseudomonas exotoxins with reduced antigenicity |
-
2008
- 2008-02-28 WO PCT/US2008/002747 patent/WO2008109005A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003027135A2 (en) * | 2001-09-26 | 2003-04-03 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
WO2003045429A2 (en) * | 2001-11-28 | 2003-06-05 | Novartis Ag | Anti-t cell immunotoxin fusion protein and its therapeutic use |
WO2005052006A2 (en) * | 2003-11-25 | 2005-06-09 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
WO2007016150A2 (en) * | 2005-07-29 | 2007-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Mutated pseudomonas exotoxins with reduced antigenicity |
Non-Patent Citations (1)
Title |
---|
DECKER THOMAS ET AL: "Induction of caspase-dependent programmed cell death in B-CLL cells by recombinant anti-CD22 immunotoxins", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 103, no. 7, 1 April 2004 (2004-04-01), pages 2718 - 2726, XP002499412, ISSN: 0006-4971 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2008109005A2 (en) | 2008-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2437875B (en) | Skin care composition comprising L-carnosine and N-acetylcysteine | |
SG129355A1 (en) | Method and structure to prevent silicide strappingof source/drain to body in semiconductor devices with source/drain stressor | |
CA125062S (en) | Bottle | |
TWI373110B (en) | Semiconductor die with through-hole via on saw streets and through-hole via in active area of die | |
EA019744B9 (en) | Isothiazolyloxyphenyl amidines and use thereof for combating fungi and seed material treated with isothiazolyloxyphenyl amidines | |
MY148995A (en) | Absorbent article | |
PT2601961T (en) | Compositions comprising lag-3 and therapeutic antibodies and their uses in the treatment of cancer | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
AU319645S (en) | Play set slide | |
AU319251S (en) | Tractor | |
AU314223S (en) | Appendage wrap | |
GT200900008A (en) | NOVEDOUS AMINOPIRIDINE DERIVATIVES THAT HAVE SELECTIVE INHIBITORY ACTION ON AURORA A | |
AU313473S (en) | Appendage wrap | |
EP2164490A4 (en) | Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain. | |
AU306408S (en) | Tractor | |
TW200730116A (en) | Pillow | |
JO3262B1 (en) | Combination of decitabine with cytidine deamiase inhibitor and use thereof in the treatment of cancer | |
AU317011S (en) | Tractor | |
GB2437149B (en) | Synergistic preservative systems and their use in cosmetic compositions. | |
WO2008054711A3 (en) | Combined telomerase inhibitor and gemcitabine for the treatment of cancer | |
MX2009012710A (en) | Skin moisturizer and use thereof. | |
WO2007124382A3 (en) | Inhaled imipenem | |
IL196603A (en) | Oroate derivatives for use in the treating tumors and hematopoietic disorders to reduce chemotherapy-induced side effects | |
WO2008109005A3 (en) | Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers | |
UA104274C2 (en) | Hydrosulphuric derivatives of non-steroidal anti-inflammatory drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08726308 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08726308 Country of ref document: EP Kind code of ref document: A2 |